Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AZD3470 in MTAP-deficient advanced solid tumors
NL-OMON59379Phase 1Recruiting
- Sponsor
- AstraZeneca
- Start
- Nov 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of AZD3470 in Nonhematologic neoplasms (3 arms), sponsored by AstraZeneca. Started Nov 2024; status: recruiting.
02
Drugs
AZD3470
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on NL-OMON59379.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59379.